• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Tsai Chung-Yi was granted 150,000 shares, increasing direct ownership by 276% to 204,400 units (SEC Form 4)

    3/12/25 11:12:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    tsai chung-yi

    (Last) (First) (Middle)
    8880 RIO SAN DIEGO DRIVE
    SUITE 800

    (Street)
    SAN DIEGO CA 92108

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Ainos, Inc. [ AIMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 03/10/2025 A 150,000(1) A $0.46 204,400 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    RSU (1) 03/10/2025 A 150,000 (1) (1) Common Stock 150,000 (1) 0 D
    RSU (1) 03/10/2025 C 150,000 (1) (1) Common Stock 150,000 (1) 0 D
    Explanation of Responses:
    1. Reference is made to the 150,000 shares of common stock granted and vested to the Reporting Person as special stock awards on March 10, 2025. The special stock awards have been approved by the stockholders of Ainos, Inc. on September 27, 2024.
    /s/ Chun-Hsien Tsai by POA for Chung-Yi Tsai 03/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AIMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tsai Chun-Jung was granted 900,000 shares, increasing direct ownership by 170% to 1,427,900 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:35 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Ting-Chuan was granted 900,000 shares, increasing direct ownership by 169% to 1,431,432 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:38 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, PRESIDENT, CHAIRMAN Tsai Chun-Hsien was granted 900,000 shares, increasing direct ownership by 120% to 1,651,862 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:36 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    SEC Filings

    See more
    • SEC Form DEF 14C filed by Ainos Inc.

      DEF 14C - Ainos, Inc. (0001014763) (Filer)

      5/29/25 4:15:06 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14C filed by Ainos Inc.

      PRE 14C - Ainos, Inc. (0001014763) (Filer)

      5/19/25 4:15:23 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ainos Inc.

      10-Q - Ainos, Inc. (0001014763) (Filer)

      5/14/25 4:05:51 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care